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The effects of Carvedilol on myocardial morphology and functional outcome were studied
in patients with chronic HM undergoing cardio-vascular bypass grafting (CABG). Nine-
teen patients (13 males, 62+/-9 years) eligible for CABG due to severe CAD were ran-
domized into two groups: patients in group 1 (n=10) received Carvedilol (25 mg/day),
patients in group 2 received placebo (n=9), starting from randomization 7-8 weeks prior
to CABG until follow-up 4-6 months postoperatively, in addition to standard antianginous
therapy and aspirin. Left ventricular ejection fraction (EF) and regional wall motion abnor-
malities (WMA, centerline method) were quantitated in cineventriculography at baseline
and follow-up. Viability was assessed by Tc99m scintigraphy and F-18-FDG positron
emission tomography. Intraoperatively, transmural needle biopsies were obtained for
microscopic analysis and immunohistochemistry from hypokinetic but viable myocardial
regions. EF in group 1 increased from 31±5% to 44±4% postoperatively (p<0.005), EF in
group 2 increased from 30±6% to 40±6% (p<0.05 versus preoperatively and versus
group 1). WMA in the center of myocardial dysfunction in group 1 increased from -
2.1±0.4 to -0.6±0.5 (p<0.05), WMA in group 2 increased from -2.3±0.5 to -1.6±0.6
(p<0.05 versus pre and versus group 1). Microscopic analysis showed mild degenerative
changes in group1 with mild fibrosis (28±7%) and no evidence for apoptosis. Biopsies in
group 2 showed more apoptotic cell changes and progressive cardiomyocyte degenera-
tion but similar mild-to modest fibrosis (33±6%). Early treatment with Carvedilol in
patients with hibernating myocardium might delay progressive cardiomyocyte degenera-
tion possibly due to anti-apoptotic and anti-oxidant effects, which might result in improved
recovery of contractile function after revascularization.
1137-94 Age and the Lack of an Adverse Effect of Diabetes 
Explain the “Obesity Paradox” in Patients With 
Myocardial Infarction
Scott Wright, Joseph G. Murphy, Thomas G. Allison, Anil Nigam, Wayne L. Miller, Brent 
A. Williams, Ana G. Rosales, Guy S. Reeder, Allan S. Jaffe, Mayo Clinic, Rochester, MN
Background: The “obesity paradox” refers to improved survival among obese patients fol-
lowing acute myocardial infarction (AMI). The nature of this remains poorly defined.
Methods: We analyzed the outcome of 941 patients with AMI from 1988 until 2001. Obe-
sity was defined as BMI > 30, overweight as 25<BMI < 30 and normal weight as BMI <
25. Univariate and multivariate predictors of survival were analyzed.
Results: Obese patients were younger and less likely to be female at time of admission
(p<0.01). The prevalence of diabetes was higher in obese patients (24%) compared to
overweight (15%) or normal weight patients (13%), p <0.05. There were no differences in
other clinical characteristics. Long-term mortality was significantly lower in the obese (RR
0.64) and overweight (RR 0.76) patients compared to normal weight patients (RR 1.0),
p=0.04. Long-term survival among all three groups was less than age-predicted (see fig-
ure). Diabetes was not a univariate predictor of mortality risk in obese patients (RR NS)
but was in non-obese patients (RR 1.77, 95% CI 1.26, 2.48), p < 0.01. After adjustment
for age and diabetes, there were no longer significant differences: Obese (RR 0.74),
overweight (RR 0.83) vs normal (RR 1.0), p=0.14. Conclusion: The obesity paradox fol-
lowing AMI appears to be largely a function of younger age at time of presentation and
the lack of impact of concomitant diabetes. When adjusted for age, the long-term RR of
death in obese and overweight patients is similar to normal weight individuals 
1137-95 Demographics, Treatment, and Outcome of Acute 
Coronary Syndromes: 17 Years of Experience in a 
Tertiary Care Center
Jean-Pierre S. Awaida, Jocelyn Dupuis, Pierre Théroux, Michel Joyal, Pierre De Guise, 
Serge Doucet, Luc Bilodeau, Jean-François Tanguay, Richard Gallo, Jean Grégoire, 
Philippe Lavoie-Lallier, Laurent Macle, Anil Nigam, Montreal Heart Institute, Montreal, 
PQ, Canada
Background: There is limited epidemiological information about the evolution of demo-
graphics, treatment, and outcome of patients admitted to tertiary coronary care units
(CCU) over the past 15 years.
Methods: We prospectively studied 18,719 patients admitted from April 1986 to March
2003 in a 22 bed CCU. The attending physicians filled in the discharge form, which was
then entered in a computer database designed for the study.
Results: From 1986 till 2003, the number of admissions increased from 937 to 1577/year
while hospital stay decreased from 7.5 to 3.5 days; mean age increased from 58.4 to
63.4 years and the proportion of males remained stable at about 70%. Use of coronary
angiograms increased from 49.8% to 81.1% of all patients while fibrinolysis dropped from
12.2% to 0%. In-hospital mortality dropped from 9% to 1.5%. The percentage of Swan-
Ganz decreased from 8.1% to 0.7% while intra-aortic balloon pump insertion remained
stable. From 1995 till 2003, the proportion of stenting during PTCA increased dramati-
cally from 0 to 86%. In the past 5 years, surgical revascularization remained stable
around 20% of all admissions.
Conclusions: There has been a tremendous increase in efficiency with approximate
doubling of the admissions turnover rate in a tertiary care CCU. Patients with acute coro-
nary syndromes are stratified faster and treated more invasively. Therapeutic advances
are reflected by an almost linear 0.5%/year decrease of in-hospital mortality. 
1137-96 Clustering of Novel Risk Factors Correlates With the 
Metabolic Syndrome
Matthew A. Hook, John H. Chiu, Arman Askari, Niranjan Seshadri, Gregory L. Pearce, 
Dennis L. Sprecher, The Cleveland Clinic Foundation, Cleveland, OH
Background: Homocysteine, fibrinogen, lipoprotein (a) (Lp(a)), and C-reactive protein
(CRP) have been shown to be independently associated with cardiovascular dis-
ease.However, little is known regarding the clustering of these novel risk markers and
their correlation to the metabolic syndrome.
Methods: Data were collected from primary and secondary prevention patients entering
a cardiology clinic (n=1306, mean age 55 +/- 9 years, 36% female (n = 469), 19% diabet-
ics (n=243), mean waist circumference 98cm, 8% current tobacco users (n=110), mean
systolic blood pressure 122 mmHg, median LDL 126 mg/dL, median HDL 43 mg/dL),
including novel risk markers. We sought to determine whether the novel risk markers
were clustered in distribution and/or correlated to the variables of metabolic syndrome,
as defined by ATP III guidelines.
Results: These four novel biomarkers were clustered more than would be expected
under the assumption of independence (p<0.001). The expression of metabolic syn-
drome increased from 11% when none of the four were elevated to 28% when 3 or 4
were elevated (p<0.001). Conclusions: Homocysteine, fibrinogen, Lp(a) and CRP clus-
ter in an elevated state and are not independent of one another. The number of elevated
novel biomarkers directly correlates to the presence of the metabolic syndrome
1137-97 Soluble CD40 Ligand in Predicting Coronary Artery 
Disease and Long-Term Outcomes in Stable Patients 
With Angiographically Defined Disease States
Jason M. Lappe', John F. Carlquist, Jeffrey L. Anderson, Matthew J. Kolek, Benjamin D. 
Horne, Bryant M. Whiting, Heath U. Jones, Robert R. Pearson, Johnny Walker, Joseph B. 
Muhlestein, LDS Hospital, Salt Lake City, UT, University of Utah, Salt Lake City, UT
Background:
Elevated levels of soluble CD40 ligand (sCD40L) have been reported in patients with
acute coronary syndrome and have been found to independently predict risk of future
events in this population. However, to date, no study has correlated sCD40L levels and
the long-term risks associated with coronary artery disease (CAD) in non-MI patients.
Methods:
Serum sCD40L levels using ELISA (R&D; Systems) were measured in 909 patients eval-
uated by angiography for the presence of CAD. Patients presenting with acute MI were
excluded. A three-way matching scheme (by age [±5 years], gender, and time period of
catheterization [±1 year]) was used to identify 303 patients with CAD (>70% stenosis in
>1 major vessel) who experienced a cardiac event (death, MI) within one year, 303
patients with CAD but with no events at one year, and 303 with no CAD.
Results:
The three groups were balanced, with patient age averaging 64 + 11 years; 74% males.
Median (SE) sCD40L levels were different for no-CAD patients (335 [60] pg/mL) com-
pared to CAD (248 [65] pg/mL, p=0.01) and to CAD/event (233 [63] pg/mL, p<0.001) but
not between CAD and CAD/event patients (p=0.24). After separating sCD40L levels into
quartiles, performing logistic regression, adjusting for standard risk factors and C-reac-
tive protein, and performing Bonferroni adjustment for multiple comparisons (p-critical =
0.017), there was a non-significant trend toward decreased risk of CAD vs no-CAD (Q4
vs. Q1: odds ratio [OR]= 0.71, 95% confidence interval [CI]=0.44-1.13, p=0.15) and CAD/
event vs no-CAD (Q4 vs. Q1: OR=0.59, CI=0.37-0.96, p=0.03), but not for CAD/event vs.
CAD (Q4 vs. Q1: OR=0.89, CI=0.56-1.41, p=0.61). Analyses showed no differences
between men and women.
Conclusions:
In contrast to previously reported information in patients with acute coronary syndrome,
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in these stable patients, elevated levels of sCD40L did not predict CAD and were not
associated with a higher risk of clinical events (death, MI). In fact, a trend towards lower
sCD40L levels in CAD compared to non-CAD patients was observed. This novel interac-
tion of sCD40L with type of presentation raises interesting questions for CAD pathogene-
sis and prognosis and should be further evaluated.
1137-98 Impact of Combination Evidence-Based Medical 
Therapy on Mortality in Patients With Acute Coronary 
Syndromes
Debabrata Mukherjee, Kartik Giri, Jianming Fang, Stanley Chetcuti, Mauro Moscucci, 
Eva Kline-Rogers, Kim A. Eagle, University of Michigan, Ann Arbor, MI
Background: Antiplatelet drugs, beta-blockers, ACE inhibitors and lipid lowering agents
have proven efficacy in reducing mortality in patients with acute coronary syndromes.
However, the impact of the combination of these agents when used together on clinical
outcomes has not been studied before.
Methods Patients presenting with acute coronary syndromes between 01/99 and 03/02
were identified. Based on discharge use of evidence-based therapies, we created a com-
posite appropriateness score depending on the number of the drugs used divided by the
number of the drugs indicated for each patient. The impact of the composite score on 6-
month mortality was analyzed using a risk-adjusted logistic regression model.
Results: The odds ratio for death for all indicated medications used (appropriateness
level IV) vs. none of the indicated medications used (appropriateness level 0) was [0.13,
95% CI 0.04-0.38, p=0.0002]; similarly for appropriateness level III vs. level 0 was [0.15,
95% CI 0.05-0.45, p=0.0008]; for appropriateness level II vs. level 0 was [0.20, 95% CI
0.06-0.64, p=0.006] and for appropriateness level I vs. level 0 was [0.28, 95% CI 0.08-
1.01, p=0.051].
Conclusions: Use of combination evidence-based medical therapies was independently
and strongly associated with lower 6-month mortality in patients with acute coronary syn-
dromes. Such therapies, most of which are generic and inexpensive today, appear to
offer a marked survival advantage when compared to patients where such therapies are
omitted. 
1137-99 Clopidogrel in Unstable Angina Patients Who Would 
Have Been Excluded From Randomized Pivotal Trials
Laurent Payot, Jean Philippe Collet, Gilles Montalescot, Rémi Choussat, Jean philippe 
Metzger, Gérard Dobrinski, Daniel Thomas, Centre Hospitalier Universitaire Pitié-
Salpétrière (AP-HP), Paris, France
Objectives:
We describe the characteristics and examine the efficacy and safety of Clopidogrel in
unstable angina /non-ST-elevation myocardial infarction (UA/NSTEMI)patients who would
have not been eligible for the Cure trial.We compared this group to the patients fitting the
Cure criteria.
Background:
It is not known whether the benefit shown with clopidogrel in the selected population of
pivotal trials can be extended to the real world.
Methods and Results:
All patients with UA/NSTEMI were anticoagulated with subcutaneous enoxaparin associ-
ated with a double antiplatelet regimen including a loading aspirin and 300mg clopidogrel
as first line medical stabilization treatment. Among 517 consecutive patients, we identi-
fied 117 patients ( "EP" for excluded patients)who would have not been eligible.This EP
group was older,had a lower creatinine clearance, had more frequently a past-history of
CABG or a diagnosis of non-Q MI on admission in comparison with patients without any
of the exclusion criteria ("NEP"for non excluded patients). Moreover the EP had a lower
ejection fraction (48% vs 55%, p<0,001), a higher TIMI risk score (3.27%vs 2.80%,
p=0.0016), a longer hospitalisation duration (3.93 days ± 2.83 vs 3.11 days ± 1.64;
p<0.0001) and a higher rate of diabetes (31.6% vs 21.7%, p<0.05). The use of GPIIb/IIIa
inhibitors was similar in the two groups (41% vs 43%, p=NS). The EP group underwent
less frequently PCI than those of the NEP group (56% vs 68%,p=0.01). There was a non
significant trend for a higher rate of major bleeding at 30-day in the EP group (5.1% vs
2.7%,p=NS). The rate of major coronary events at 30 days (myocardial infarction and
death) was higher in the EP group (14.5% vs 4.5%, p =0.0013). When considering
severe renal failure (creatinine clearance<30 ml/min), there was still no significant differ-
ence in the rate of major bleeding (5.62 vs 2.24, p= 0.06), although the number of EP
rose up to 160.
Conclusion:
Patients who do not fit the enrolment criteria of Cure trials have higher risk baseline char-
acteristics for both bleedings and ischemic events. In these patients, the use of clopi-
dogrel was associated with a moderate and non significant increase of bleedings
compared to typical "CURE" patients.
1137-100 Five-Year Survival Data From the APRICOT Trials: Does 
Female Gender Really Portend Unfavorable Outcome?
Hendrik-Jan Dieker, Nick Clappers, Peter C. Kievit, Marc A. Brouwer, Paul J.P.C. van den 
Bergh, Wim R.M. Aengevaeren, Gerrit Veen, Freek W.A. Verheugt, University Medical 
Center St. Radboud, Nijmegen, The Netherlands
Background: Few studies have thoroughly addressed the unfavorable outcome of
women after acute MI, especially in the long-term; discussion remains with respect to the
impact of clinical and angiographic baseline differences. This is the scope of the current
5-year survival study.
Methods: Patients (n=452) had fibrinolysis (FL) for acute STEMI and an open infarct
artery at 24-hour angiography. Three-month follow-up (FU) angiography and 5-year clini-
cal FU (97%) were obtained.
Results: Of the 452 patients 75 (17%) were female. Women were older (59+11 vs. 56+9
yrs, p>0.01), more often known with hypertension (39% vs. 22%, p>0.01) and more often
smokers than men (73% vs. 63%, p=0.08). Single vessel disease was more frequent
among women: 69% vs. 54% (p=0.01). Baseline stenosis severity (QCA) was less
severe: 54+14 vs. 58+13 (p=0.04). The 3-month reocclusion rate was similar in men and
women (20% vs. 19%). 5-year survival did not differ (89% vs. 91%). Gender was not
independently associated with survival.
Conclusions: Survival 5 years after successful FL did not differ between men and
women, despite a less favorable clinical baseline profile. Women more often had single
vessel disease and less severe culprit lesions, but similar reocclusion rates. These find-
ings after successful FL challenge the often generalized association between gender and
outcome and warrant further exploration as to whether this relationship is primarily driven
by an association in the subset of patients after failed FL. 
1137-101 Elevated Parathyroid Hormone Is an Important Predictor 
of Coronary Events in Patients With Chronic 
Hemodialysis
Takashi Kubo, Takuzo Hano, Masahiro Obana, Toshio Imanishi, Akira Baba, Kazushi 
Tsuda, Yoshiaki Tomobuchi, Mikio Arita, Ichiro Nishio, Wakayama Medical University, 
Wakayama, Japan
BACKGROUND: Secondary hyperparathyroidism is prevalent among patients with
chronic hemodialysis and influences the calcium metabolism. Excess of parathyroid hor-
mone (PTH) may play an important role in the development of coronary calcification and
atheroscrelosis. The aim of this study was to evaluate whether serum levels of PTH can
predict risk for future coronary events.
METHODS: A consecutive series of 104 patients with chronic hemodialysis undergoing
coronary angiography were enrolled in this study. We measured baseline serum intact
PTH levels and long-term clinical outcomes were obtained. The incidence of coronary
events (stable angina, unstable angina and acute myocardial infarction) due to new coro-
nary lesions confirmed by angiography was compared with the serum intact PTH levels.
RESULTS: The prevalence of secondary hyperparathyroidism (intact PTH > or = 65 pg/
ml, 311 +/- 284.1 pg/ml, mean +/- SD) was 60 of 104 patients (58%). During 3-year fol-
low-up, the incidence of coronary events associated with new coronary lesions was sig-
nificantly higher in patients with hyperparathyroidism than that in patients with normal
PTH (27% vs. 5%, p<0.001). Univariate Cox regression analysis demonstrated that dia-
betes (HR=10.4, 95% CI=2.4 to 45.2, p=0.002), hyperparathyroidism (HR=7.8, 95%
CI=1.8 to 34.3, p=0.006), obesity (HR=3.3, 95% CI=1.3 to 8.3, p=0.013) and hyperlipi-
demia (HR=2.6, 95% CI=1.1 to 6.6, p=0.042) were significant predictors of the develop-
ing coronary events, however, age, sex, duration of hemodialysis and other conventional
risk factors were not. In a multivariate analysis, hyperparathyroidism remained an inde-
pendent predictor of developing coronary events (HR=5.5, 95% CI=1.2 to 25.5, p=0.028).
CONCLUSION: In patients with chronic hemodialysis, the elevated PTH was an indepen-
dent and strong predictor of coronary events after adjusting for conventional risk factors.
